Abstract: A polyfunctional organohydrogensiloxane is prepared using a boron containing Lewis acid as catalyst. The polyfunctional organohydrogensiloxane may be formulated into release coating compositions. Alternatively, the polyfunctional organohydrogensiloxane may be further functionalized with a curable group to form a clustered functional organosiloxane. The clustered functional organosiloxane may be formulated into thermal radical cure adhesive compositions.

Abstract: Provided are a communication station, an optical communication system, a data transmission method, and a storage medium. The communication station is a first station including: a first reconfigurable optical add-drop multiplexing ROADM device, including a first port used to connect a cable in a first direction of a network; a second ROADM device connected to the first ROADM device and including a second port which may be used to connect a cable in a second direction of the network being different from the first direction; an optical protection device connected to each of the first and second ROADM devices and used to control the first station to transmit communication with a second station for a corresponding service in the first direction corresponding to the first ROADM device, or to transmit communication with the second station for a corresponding service in the second direction corresponding to the second ROADM device.

Abstract: A particle separator assembly includes an airbox providing an outer tapered portion tapering from a first section having a first cross sectional area to a first opening having a second cross sectional area less than the first cross sectional area. The example assembly includes a flow diverter providing an inner tapered portion that tapers to a second opening. The example assembly includes an air filter housed by the airbox, the air filter is spaced from the second opening in a first direction, and the first opening is spaced from the second opening in a second direction opposite the first direction.

Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.

Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.

Abstract: Disclosed herein are related to coordinating communication among a first access point, a first station device, a second access point, and a second station device. In one aspect, the second access point receives, from the first access point, a first beacon of the first access point at a first beacon transmission time. The first beacon may indicate an offset between the first beacon transmission time of the first beacon and a first data transmission time of the first access point for communication between the first access point and a first station device. In one aspect, the second access point may determine, according to the offset, a second data transmission time of the second access point to be distinct from the first data transmission time of the first access point. The second access point may communicate with a second station device, according to the second data transmission time.

Abstract: Disclosed herein are related to a system and a method of remotely rendering artificial reality. In one approach, a console determines an expected transmission end time of a first session for wireless transmission of image data indicating an image of artificial reality to a head wearable display. In one approach, the console determines an expected process end time of generating additional data associated with the image of the artificial reality. In one approach, the console compares the expected transmission end time and the expected process end time. The console may transmit, to the head wearable display in the first session, the additional data together with the image data, in response to the expected process end time being less than the expected transmission end time.

Abstract: A composition contains an organopolysiloxane having the following average chemical structure: X3SiO—SiR2—R?—(R2SiO)x—R2Si—[Rb—(R2SiO)y—R2Si—Rb?—(R2SiO)z—R2Si]m—R?—R2SiO—SiX3; where X is —OSiR2—R?—R2SiO—R2Si—R?-A; R is an alkyl group having from 2 to 6 carbons and aryl groups; R?, R?, Rb and Rb? are divalent hydrocarbon groups comprising a chain of 2 to 6 methylene units; A is acrylate, methacrylate or trialkoxysilyl; provided that, on average, 60 to 90 mole-percent of the A groups are acrylate and methacrylate; Subscript m has an average value in a range of zero to 10; Subscripts x, y and z each has an average value in a range of zero to 1200; and provided that the average values of m, x, y and z are such that the sum of the average values for x, y and z is in a range of 300-1200 and the molar ratio of methylene units to siloxane units is less than 0.15.

Abstract: A curable organopolysiloxane composition contains: (A) 100 mass parts of a functional organopolysiloxane component having at least one radical curable group selected from an acrylate group and a methacrylate group and optionally one or more alkoxysilyl groups; (B) 0 to 100 mass parts of a condensation curable organo polysiloxane component; (C) one to 10 mass parts of tetraalkoxysilanes or a hydrolyate of the tetraalkoxysilanes; and optionally one or more of (D) a radical initiator, (E) a condensation catalyst, (F) fillers, (G) adhesion promoters, (H) pigments, (I) a non-reactive organopolysiloxane, and (J) inhibitors.

Abstract: A composition contains: (a) a first organopolysiloxane with an average of 2 or more mercaptoalkyl groups per molecule and that is free of alkenyl functionality; (b) a second organopolysiloxane with an average of one or more alkenyl group and one or more alkoxy group per molecule; (c) a tetraalkoxy silane; (d) an ultraviolet light photoinitiator; and (E) a condensation catalyst; where the concentration of the first and second organopolysiloxanes are such that the molar ratio of mercaptoalkyl groups to alkenyl groups is in a range of 0.4 to 3.0.

Abstract: Disclosed herein are related to a first device to communicate with a second device and a third device. In one aspect, the first device determines a first time interval to receive a first beacon frame from the second device. In one aspect, the first device determines, according to the first time interval, a second time interval for the first device to transmit a second beacon frame to a third device. In one aspect, the first device determines a third time interval to operate the first device in a wake up mode. The third time interval may encompass the first time interval and the second time interval. In one aspect, the first device receives the first beacon frame from the second device during the first time interval, and transmits the second beacon frame to the third device during the second time interval.

Abstract: Disclosed herein a system, a method and a device for dynamic scheduling between a head wearable display and a console is provided. The head wearable display can initiate, at a first time instance, a first downlink transmission to the console. The head wearable display can dynamically indicate, to the console, an end of the first downlink transmission, at a second time instance when transfer of data of the first downlink transmission is complete. The head wearable display can dynamically cause, relative to the second time instance, the console to begin an uplink transmission. The head wearable display can receive an indication to dynamically start a second downlink transmission, at a third time instance when transfer of data of the uplink transmission is complete.

Abstract: A composition contains an organopolysiloxane having the following average chemical structure: X3SiO—SiR2—R?—(R2SiO)x—R2Si—[Rb—(R2SiO)y—R2Si—Rb?—(R2SiO)z—R2Si]m—R?—R2SiO—SiX3; where X is —OSiR2—R?—R2SiO—R2Si—R?-A; R is an alkyl group having from 2 to 6 carbons and aryl groups; R?, R?, Rb and Rb? are divalent hydrocarbon groups comprising a chain of 2 to 6 methylene units; A is acrylate, methacrylate or trialkoxysilyl; provided that, on average, 60 to 90 mole-percent of the A groups are acrylate and methacrylate; Subscript m has an average value in a range of zero to 10; Subscripts x, y and z each has an average value in a range of zero to 1200; and provided that the average values of m, x, y and z are such that the sum of the average values for x, y and z is in a range of 300-1200 and the molar ratio of methylene units to siloxane units is less than 0.15.

Abstract: An application of a heterocyclic compound. An application of a substance Y in the preparation of drugs for raising blood sugar. The compound can be used to raise blood sugar and treat hypoglycemia or congenital hyperinsulinism.

Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.

Abstract: Polyorganosiloxanes and methods for their preparation are disclosed. The polyorganosiloxanes are useful in curable compositions. The polyorganosiloxanes may have up to 9 silicon bonded hydrogen atoms, or other curable groups, per molecule.

Abstract: Disclosed herein includes a system, a method, and a device for prioritizing packet retransmission. A transmitting device can insert, for each packet of a plurality of packets of a video frame, a sequence number indicative of an order of the corresponding packet among the plurality of packets, into a header of the corresponding packet according to an application layer protocol. The transmitting device can transmit to the receiving device, at a first level of priority, the plurality of packets including the corresponding inserted sequence numbers. The transmitting device can receive an identification of one or more packets to be retransmitted to the receiving device, the identification based on at least the inserted sequence numbers of the one or more packets. The transmitting device can retransmit the one or more packets at a second level of priority that is higher than the first level of priority.

Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:

Abstract: Systems and methods for iterative distributed beam selection include a device including at least one of a first head wearable display (HWD), a second HWD, a first console or a second console. The device detects a predefined condition. The device performs a first distributed beam selection responsive to detecting the predefined condition. Performing the first distributed beam selection includes performing beamforming to provide a first plurality of beams for a first link between the first HWD and the first console, selecting a first beam of the first link with a highest signal-to-interference-plus-noise ratio (SINR) from the first plurality of beams, performing beamforming to provide a second plurality of beams for a second link between the second HWD and the second console while the first beam of the first link is active, and selecting a second beam of the second link with a highest SINR from the second plurality of beams.

Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.